Scarica l'app Stockscreener
111.67
4.25%
-4.96
Pre-mercato:
111.01
-0.66
-0.59%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Precedente Chiudi:
$116.63
Aprire:
$112.43
Volume 24 ore:
1.67M
Relative Volume:
1.86
Capitalizzazione di mercato:
$5.45B
Reddito:
$338.46M
Utile/perdita netta:
$-310.96M
Rapporto P/E:
-17.10
EPS:
-6.53
Flusso di cassa netto:
$-132.82M
1 W Prestazione:
-7.22%
1M Prestazione:
-12.44%
6M Prestazione:
+23.38%
1 anno Prestazione:
+45.04%
Intervallo 1D:
$107.00
$113.73
Intervallo di 1 settimana:
$107.00
$122.97
Portata 52W:
$64.11
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Nome
Axsome Therapeutics Inc
Settore
Industria
Telefono
(212) 332-3241
Indirizzo
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
Confronta AXSM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
111.67 | 5.45B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-31 | Reiterato | Mizuho | Outperform |
| 2024-09-03 | Iniziato | Wells Fargo | Overweight |
| 2024-08-06 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-04-29 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2024-01-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-08-08 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Iniziato | Piper Sandler | Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2022-09-07 | Ripresa | Mizuho | Buy |
| 2021-08-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Iniziato | Berenberg | Buy |
| 2021-01-08 | Iniziato | Jefferies | Buy |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-09-29 | Iniziato | BofA Securities | Underperform |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-14 | Iniziato | Cowen | Outperform |
| 2019-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-16 | Reiterato | Guggenheim | Buy |
| 2019-10-16 | Iniziato | Guggenheim | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-28 | Iniziato | SunTrust | Buy |
| 2019-05-23 | Reiterato | H.C. Wainwright | Buy |
| 2019-04-08 | Iniziato | SVB Leerink | Outperform |
| 2019-03-15 | Reiterato | H.C. Wainwright | Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2015-12-15 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
Corient Private Wealth LLC Makes New Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Plans Excessive Sleepiness Study In Depression After Phase III Failure - insights.citeline.com
Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week - MSN
Why Shares of Axsome Therapeutics Slumped Today - The Motley Fool
Why Shares of Axsome Therapeutics Slumped Today - Nasdaq
Axsome shares fall after trial results disappoint By Investing.com - Investing.com Canada
Axsome Must Face Securities Fraud Suit Over Migraine Drug Delays - Bloomberg Law News
Axsome falls on depression drug's trial setback - TradingView
Mizuho maintains Axsome stock Outperform amid trial setback - Investing.com
BofA maintains Buy rating on Axsome shares with $174 target - Investing.com
Guggenheim maintains Buy on Axsome stock, price target at $195 - Investing.com India
Axsome's Solriamfetol Fails Primary Goal In Depression Study But Shows Improvements In Associated Sleep Disorder - Benzinga
Axsome Therapeutics: Promising Market Opportunity for Solriamfetol in Severe EDS Subgroup Boosts Buy Rating - TipRanks
Positive Outlook for Axsome Therapeutics Amid Mixed Trial Results and Upcoming FDA Application - TipRanks
P2P Group Ltd. Investor Presentation - The Globe and Mail
Axsome to narrow focus of depression drug trial after limited success in initial run - MarketScreener
Axsome stock slips as depression trial fails (AXSM:NASDAQ) - Seeking Alpha
S&P 500 Futures Fall in Premarket Trading; Axsome Therapeutics, First Horizon Lag - MarketWatch
Why Is Axsome Therapeutics Stock Falling In Pre-market? - Nasdaq
Axsome’s solriamfetol shows promise in MDD with EDS subgrou - Investing.com
Axsome's depression treatment fails to meet main goal of late-stage study - TradingView
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS) - Financial Post
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of - Bluefield Daily Telegraph
DnB Asset Management AS Has $6.24 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $216.00 - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Buy" by Analysts - MarketBeat
Loomis Sayles & Co. L P Sells 8,475 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Down 4.9%Here's Why - MarketBeat
Fox Run Management L.L.C. Makes New $518,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
(AXSM) Proactive Strategies - Stock Traders Daily
Cibc World Markets Corp Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome succeeds in late-stage trial for ADHD therapy - MSN
Celanese To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Breaking Down Axsome Therapeutics: 31 Analysts Share Their Views - Benzinga
Medical Properties Trust : Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint - MarketScreener
Bayer gains cancer drug from China’s Puhe; Axsome gets mixed ADHD data - BioPharma Dive
AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint - Yahoo Finance
Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail
Mizuho Securities Adjusts Axsome Therapeutics Price Target to $216 From $212, Maintains Outperform Rating - Marketscreener.com
Axsome’s Sunosi succeeds in Phase III ADHD trial - Yahoo Finance
13,460 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by HighTower Advisors LLC - MarketBeat
Intech Investment Management LLC Acquires 5,087 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome’s latest win comes in ADHD, Opthea seeks path after AMD miss, and more: Clinical Report - biocentury.com
Axsome’s Scores In ADHD, But Differentiation In Generic-Heavy Market Unclear - insights.citeline.com
Axsome reports Phase 3 win for Sunosi in adults with ADHD, with a high-dose caveat - Endpoints News
Axsome Therapeutics’ Promising Phase III FOCUS Trial Results Boost Buy Rating - TipRanks
Axsome shares fall after ADHD trial results By Investing.com - Investing.com UK
Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal - Benzinga
Axsome stock rises on trial win for ADHD drug (AXSM:NASDAQ) - Seeking Alpha
Axsome Therapeutics' ADHD Trial Achieves Primary, Key Secondary Endpoints - Nasdaq
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint - MarketScreener
Axsome Therapeutics Inc Azioni (AXSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Axsome Therapeutics Inc Azioni (AXSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pizzie Nick | Chief Financial Officer |
Feb 14 '25 |
Option Exercise |
3.50 |
3,000 |
10,500 |
45,187 |
| Pizzie Nick | Chief Financial Officer |
Feb 13 '25 |
Sale |
129.86 |
12,000 |
1,558,320 |
42,187 |
| Pizzie Nick | Chief Financial Officer |
Feb 14 '25 |
Sale |
131.07 |
3,000 |
393,210 |
42,187 |
3.89%
0.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):